866-997-4948(US-Canada Toll Free)

Male Health Drug Development Pipeline Review, 2017

Published By :

GBI Research

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 125 Pages

Male Health Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the pipeline landscape for male health. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia, and features dormant and discontinued projects.

Male hypogonadism is a condition in which the body doesnt produce enough testosterone, resulting in signs and symptoms of testosterone deficiency and/or infertility. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis).

Erectile dysfunction is the inability of a man to achieve and sustain an erection sufficient to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Benign prostatic hyperplasia is the enlargement of the prostate gland and occurs when cells of the prostate gland begin to multiply. Symptoms include painful urination, leakage of urine, nocturia and blood in the urine.

The size of these pipelines ranges from 23 products in male hypogonadism to 36 in erectile dysfunction. Across all three of these indications, however, androgen receptors and phosphodiesterase 5 are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

- Which companies are the most active within the pipeline for male health therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of male health?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Male Health Report Coverage 8
2.2 Male Hypogonadism - Overview 8
2.3 Erectile Dysfunction - Overview 8
2.4 Benign Prostatic Hyperplasia - Overview 8
3 Therapeutics Development 9
3.1 Male Hypogonadism 9
3.2 Erectile Dysfunction 15
3.3 Benign Prostatic Hyperplasia 22
4 Therapeutics Assessment 29
4.1 Male Hypogonadism 29
4.2 Erectile Dysfunction 36
4.3 Benign Prostatic Hyperplasia 43
5 Companies Involved in Therapeutics Development 52
5.1 Male Hypogonadism 52
5.2 Erectile Dysfunction 58
5.3 Benign Prostatic Hyperplasia 71
6 Dormant Projects 84
6.1 Male Hypogonadism 84
6.2 Erectile Dysfunction 85
6.3 Benign Prostatic Hyperplasia 88
7 Discontinued Products 90
7.1 Male Hypogonadism 90
7.2 Erectile Dysfunction 90
7.3 Benign Prostatic Hyperplasia 91
8 Product Development Milestones 92
8.1 Male Hypogonadism 92
8.2 Erectile Dysfunction 103
8.3 Benign Prostatic Hyperplasia 111
9 Appendix 124
9.1 Methodology 124
9.2 Coverage 124
9.3 Secondary Research 124
9.4 Primary Research 124
9.5 Expert Panel Validation 124
9.6 Contact Us 125
9.7 Disclaimer 125

1.1 List of Tables
Table 1: Number of Products under Development for Male Hypogonadism, H2 2017 9
Table 2: Number of Products under Development by Companies, H2 2017 11
Table 3: Number of Products under Development by Universities/Institutes, H2 2017 12
Table 4: Products under Development by Companies, H2 2017 13
Table 5: Products under Development by Universities/Institutes, H2 2017 14
Table 6: Number of Products under Development for Erectile Dysfunction, H2 2017 15
Table 7: Number of Products under Development by Companies, H2 2017 17
Table 8: Number of Products under Development by Universities/Institutes, H2 2017 18
Table 9: Products under Development by Companies, H2 2017 19
Table 10: Products under Development by Universities/Institutes, H2 2017 21
Table 11: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 22
Table 12: Number of Products under Development by Companies, H2 2017 24
Table 13: Number of Products under Development by Universities/Institutes, H2 2017 25
Table 14: Products under Development by Companies, H2 2017 26
Table 15: Products under Development by Universities/Institutes, H2 2017 28
Table 16: Number of Products by Stage and Target, H2 2017 30
Table 17: Number of Products by Stage and Mechanism of Action, H2 2017 32
Table 18: Number of Products by Stage and Route of Administration, H2 2017 34
Table 19: Number of Products by Stage and Molecule Type, H2 2017 36
Table 20: Number of Products by Stage and Target, H2 2017 37
Table 21: Number of Products by Stage and Mechanism of Action, H2 2017 39
Table 22: Number of Products by Stage and Route of Administration, H2 2017 41
Table 23: Number of Products by Stage and Molecule Type, H2 2017 43
Table 24: Number of Products by Stage and Target, H2 2017 45
Table 25: Number of Products by Stage and Mechanism of Action, H2 2017 47
Table 26: Number of Products by Stage and Route of Administration, H2 2017 49
Table 27: Number of Products by Stage and Molecule Type, H2 2017 51
Table 28: Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017 52
Table 29: Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017 52
Table 30: Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017 53
Table 31: Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017 53
Table 32: Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017 54
Table 33: Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017 54
Table 34: Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017 55
Table 35: Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017 55
Table 36: Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017 56
Table 37: Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017 56
Table 38: Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017 57
Table 39: Male Hypogonadism - Pipeline by The Female Health Company, H2 2017 58
Table 40: Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017 58
Table 41: Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2017 58
Table 42: Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2017 59
Table 43: Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2017 59
Table 44: Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2017 60
Table 45: Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2017 60
Table 46: Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017 61
Table 47: Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2017 61
Table 48: Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 62
Table 49: Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2017 62
Table 50: Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2017 63
Table 51: Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2017 63
Table 52: Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H2 2017 64
Table 53: Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2017 64
Table 54: Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 65
Table 55: Erectile Dysfunction - Pipeline by Monosol Rx LLC, H2 2017 65
Table 56: Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2017 66
Table 57: Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017 66
Table 58: Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017 67
Table 59: Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017 67
Table 60: Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2017 68
Table 61: Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2017 68
Table 62: Erectile Dysfunction - Pipeline by Suda Ltd, H2 2017 69
Table 63: Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2017 69
Table 64: Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2017 70
Table 65: Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H2 2017 70
Table 66: Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017 71
Table 67: Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017 71
Table 68: Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017 72
Table 69: Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017 72
Table 70: Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017 73
Table 71: Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 73
Table 72: Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017 74
Table 73: Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017 74
Table 74: Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017 75
Table 75: Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017 75
Table 76: Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 76
Table 77: Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017 76
Table 78: Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017 77
Table 79: Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017 77
Table 80: Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017 78
Table 81: Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 78
Table 82: Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017 79
Table 83: Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017 79
Table 84: Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017 80
Table 85: Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 80
Table 86: Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017 81
Table 87: Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017 81
Table 88: Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017 82
Table 89: Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017 83
Table 90: Male Hypogonadism - Dormant Projects, H2 2017 84
Table 91: Erectile Dysfunction - Dormant Projects, H2 2017 85
Table 92: Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 88
Table 93: Male Hypogonadism - Discontinued Products, H2 2017 90
Table 94: Erectile Dysfunction - Discontinued Products, H2 2017 90
Table 95: Benign Prostatic Hyperplasia - Discontinued Products, H2 2017 91

1.2 List of Figures
Figure 1: Number of Products under Development for Male Hypogonadism, H2 2017 9
Figure 2: Number of Products under Development by Companies, H2 2017 10
Figure 3: Number of Products under Development for Erectile Dysfunction, H2 2017 15
Figure 4: Number of Products under Development by Companies, H2 2017 16
Figure 5: Number of Products under Development by Universities/Institutes, H2 2017 18
Figure 6: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 22
Figure 7: Number of Products under Development by Companies, H2 2017 23
Figure 8: Number of Products under Development by Universities/Institutes, H2 2017 25
Figure 9: Number of Products by Targets, H2 2017 29
Figure 10: Number of Products by Stage and Targets, H2 2017 29
Figure 11: Number of Products by Mechanism of Actions, H2 2017 31
Figure 12: Number of Products by Stage and Mechanism of Actions, H2 2017 31
Figure 13: Number of Products by Routes of Administration, H2 2017 33
Figure 14: Number of Products by Stage and Routes of Administration, H2 2017 33
Figure 15: Number of Products by Molecule Types, H2 2017 35
Figure 16: Number of Products by Stage and Molecule Types, H2 2017 35
Figure 17: Number of Products by Top 10 Targets, H2 2017 36
Figure 18: Number of Products by Stage and Top 10 Targets, H2 2017 37
Figure 19: Number of Products by Top 10 Mechanism of Actions, H2 2017 38
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 38
Figure 21: Number of Products by Routes of Administration, H2 2017 40
Figure 22: Number of Products by Stage and Routes of Administration, H2 2017 40
Figure 23: Number of Products by Molecule Types, H2 2017 42
Figure 24: Number of Products by Stage and Molecule Types, H2 2017 42
Figure 25: Number of Products by Top 10 Targets, H2 2017 43
Figure 26: Number of Products by Stage and Top 10 Targets, H2 2017 44
Figure 27: Number of Products by Top 10 Mechanism of Actions, H2 2017 46
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 46
Figure 29: Number of Products by Routes of Administration, H2 2017 48
Figure 30: Number of Products by Stage and Routes of Administration, H2 2017 48
Figure 31: Number of Products by Molecule Types, H2 2017 50
Figure 32: Number of Products by Stage and Molecule Types, H2 2017 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *